Hepatocellular carcinoma remains one of oncology's most difficult frontiers — most patients are diagnosed at an advanced stage where systemic therapy is the only option, yet survival gains have historically been modest. A comprehensive network meta-analysis now offers the clearest comparative ranking yet of modern first-line regimens, with findings that may shift how clinicians weigh immunotherapy combinations against established targeted agents.
Drawing on 17 Phase III randomized controlled trials encompassing 12,727 patients, researchers pooled hazard ratios across multiple treatment arms using a random-effects network meta-analysis framework — a methodology that enables indirect comparisons between regimens never tested head-to-head. Among five regimens demonstrating superior overall survival versus sorafenib, the dual checkpoint inhibitor combination nivolumab plus ipilimumab (anti-PD-1 plus anti-CTLA-4) earned the highest p-score ranking across overall survival, progression-free survival, and objective response rate among FDA- and EMA-approved options, with a hazard ratio of 0.61 versus sorafenib and 0.70 versus lenvatinib. The anti-PD-L1/VEGF pairing atezolizumab-bevacizumab and the durvalumab-tremelimumab combination also outperformed sorafenib on overall survival, while sintilimab-bevacizumab biosimilar and camrelizumab-rivoceranib rounded out the efficacious group.
This analysis arrives at a pivotal juncture: the field has moved decisively from single-agent kinase inhibitors toward combination immunotherapy, but direct head-to-head trials between modern regimens are scarce. Network meta-analyses fill this evidence gap, though they carry inherent limitations — patient-level heterogeneity, differences in geographic enrollment, and varying hepatitis B/C prevalence across trials can confound cross-study comparisons. The nivolumab-ipilimumab pairing's ranking is notable given CTLA-4 blockade's distinct immune-priming mechanism, though its toxicity burden warrants careful patient selection. This analysis is confirmatory for immunotherapy's dominance in HCC but is potentially practice-informing in clarifying the relative positioning of dual checkpoint blockade against PD-L1/VEGF combinations — an incremental but clinically meaningful contribution.